Literaturverzeichnis

[1] Metcalfe, W.; Simpson, M.; Khan, I. H.; Prescott, G. J.; Simpson, K.; Smith, W. C. und Mac-Leod, A. M. (2002): Scottish renal registry: Acute renal failure requiring renal replacement therapy: incidence and outcome., QJM 2002 [95], Seite 579-583.

[2] Kribben, A.; Herget-Rosenthal, S.; Pietruck, F. und Philipp, T. (2003): Das akute Nierenversagen - Eine Übersicht, Dtsch.Med.Wochenschr. 2003 [128], Seite 1231-1236.

[3] Frei, U. und Schober-Halstenberg, HJ (2002): Nierenersatztherapie in Deutschland: Bericht über Dialysebehandlung und Nierentransplantation in Deutschland 2001/2002., Quasi-Niere.

[4] National Kidney Foundation (2004): K/DOQI Clinical Guidlines for Chronic Kidney Disease: Executive Summary., National Kidney Foundation, New York [2002].

[5] Van Biesen, W.; Vanholder, R. C.; Veys, N; Dhondt, A und Lameire, N. (2000): An Evaluation of an Integrative Care Approach for End-Stage Renal Disease Patients, J Am Soc Nephrol 11, Seite 116-125.

[6] Vanholder, R.; Van Loo, A.; Heering, P.; Van Biesen, W.; Lambert, M. C.; Hesse, U.; Van Der Vennet, M.; Grabensee, M. und Lameire, N. (1999): Reduced incidence of acute renal graft failure in patients treated with peritoneal dialysis compared to hemodialysis., Am J Kidney Dis. 33, Seite 934-940.

[7] Van Biesen, W.; Vanholder, R.; Van Loo, A.; Van Der Vennet, M. und Lameire, N. (1999): Peritoneal dialysis favorable influences immediate recovery of renal function after renal transplantation., Transplantation.

[8] Diaz-Buxo, J.; Walker, P.; Burgess, W.; Farmer, C.; Chandler, J. und Faircloth, W. (1986): The influence of peritoneal dialysis on the outcome of transplantation., Int.J Artif.Organs 9, Seite 359-362.

[9] Di Paolo, N. und Sacchi, G. (1990): Anatomy and physiology of the peritoneal membrane, Contrib.Nephrol 84, Seite 10-26. URL: PM:0002261778

[10] Dobbie, J. W. (1989): Morphology of the peritoneum in CAPD, Blood Purif. 7 [2-3], Seite 74-85. URL: PM:0002663038

[11] Holmes, C. J. (1994): Peritoneal host defense mechanisms in peritoneal dialysis, Kidney Int.Suppl 48, Seite S58-S70. URL: PM:0007700043

[12] Dobbie, J. W. (1992): Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis, Perit.Dial Int. 12 [1], Seite 14-27. URL: PM:0001347465

[13] Pollock, C. A.; Ibels, L. S.; Eckstein, R. P.; Graham, J. C.; Caterson, R. J.; Mahony, J. F. und Sheil, A. G. (1989): Peritoneal morphology on maintenance dialysis, Am.J.Nephrol. 9 [3], Seite 198-204. URL: PM:2667361

[14] Verger, C.; Brunschvicg, O.; Le Charpentier, Y.; Lavergne, A. und Vantelon, J. (1981): Structural and ultrastructural peritoneal membrane changes and permeability alterations during continuous ambulatory peritoneal dialysis, Proc.Eur.Dial.Transplant.Assoc. 18, Seite 199-205. URL: PM:7329968

[15] Dobbie, J. W.; Lloyd, J. K. und Gall, C. A. (1990): Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients, Adv.Perit.Dial 6, Seite 3-12. URL: PM:0001982832

[16] Di Paolo, N.; Sacchi, G.; De Mia, M.; Gaggiotti, E.; Capotondo, L.; Rossi, P.; Bernini, M.; Pucci, A. M.; Ibba, L. und Sabatelli, P. (1986): Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis, Nephron 44 [3], Seite 204-211. URL: PM:0003785484

[17] Williams, J. D.; Craig, K. J.; Topley, N; Von Ruhland, C.; Fallon, M.; Newman, G. R.; Mackenzie, R. K. und Williams, G. T. (2002): Morphologic Changes in the Peritoneal Membrane of Patients with Renal Disease., J Am Soc Nephrol 13, Seite 470-479.

[18] Rubin, J.; Herrera, G. A. und Collins, D. (1991): An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis, Am.J.Kidney Dis. 18 [1], Seite 97-102. URL: PM:2063862

[19] Davies, S. J.; Phillips, L.; Naish, P. F. und Russell, G. I. (2001): Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis, J.Am.Soc.Nephrol. 12 [5], Seite 1046-1051. URL: PM:11316864

[20] Jörres, A.; Gahl, G. M.; Ludat, K.; Frei, U. und Passlick-Deetjen, J. (1997): In vitro biocompatibility evaluation of a novel bicarbonate-buffered amino-acid solution for peritoneal dialysis, Nephrol Dial Transplant 12 [3], Seite 543-549. URL: PM:0009075138

[21] Steinhauer, H. B.; Frei, A.; Dreyling, K. W. und Schollmeyer, P. (1987): Changes of eicosanoid metabolism in CAPD-associated peritonitis, Contrib.Nephrol. 57, Seite 45-54. URL: PM:3677702

[22] Steinhauer, H. B. und Schollmeyer, P. (1986): Prostaglandin-mediated loss of proteins during peritonitis in continuous ambulatory peritoneal dialysis, Kidney Int. 29 [2], Seite 584-590. URL: PM:3457982

[23] Steinhauer, H. B.; Gunter, B. und Schollmeyer, P. (1985): Stimulation of peritoneal synthesis of vasoactive prostaglandins during peritonitis in patients on continuous ambulatory peritoneal dialysis, Eur.J.Clin.Invest 15 [1], Seite 1-5. URL: PM:3921379

[24] Goldstein, C. S.; Bomalaski, J. S.; Zurier, R. B.; Neilson, E. G. und Douglas, S. D. (1984): Analysis of peritoneal macrophages in continuous ambulatory peritoneal dialysis patients, Kidney Int. 26 [5], Seite 733-740. URL: PM:6596459

[25] Goldman, M.; Vandenabeele, P.; Moulart, J.; Amraoui, Z.; Abramowicz, D.; Nortier, J.; Vanherweghem, J. L. und Fiers, W. (1990): Intraperitoneal secretion of interleukin-6 during continuous ambulatory peritoneal dialysis, Nephron 56 [3], Seite 277-280. URL: PM:0002077410

[26] Brauner, A.; Hylander, B. und Wretlind, B. (1993): Interleukin-6 and interleukin-8 in dialysate and serum from patients on continuous ambulatory peritoneal dialysis, Am J Kidney Dis. 22 [3], Seite 430-435. URL: PM:0008372840

[27] Zemel, D.; Krediet, R. T.; Koomen, G. C.; Kortekaas, W. M.; Geertzen, H. G. und ten Berge, R. J. (1994): Interleukin-8 during peritonitis in patients treated with CAPD; an in- vivo model of acute inflammation, Nephrol Dial Transplant 9 [2], Seite 169-174. URL: PM:0008190331

[28] Stylianou, E.; Jenner, L. A.; Davies, M.; Coles, G. A. und Williams, J. D. (1990): Isolation, culture and characterization of human peritoneal mesothelial cells, Kidney Int. 37 [6], Seite 1563-1570. URL: PM:0002362409

[29] Jörres, A.; Ludat, K.; Lang, J.; Sander, K.; Gahl, G. M.; Frei, U.; DeJonge, K.; Williams, J. D. und Topley, N. (1996): Establishment and functional characterization of human peritoneal fibroblasts in culture: regulation of interleukin-6 production by proinflammatory cytokines, J Am Soc Nephrol 7 [10], Seite 2192-2201. URL: PM:0008915980

[30] Topley, N.; Mackenzie, R.; Jorres, A.; Coles, G. A.; Davies, M. und Williams, J. D. (1993): Cytokine networks in continuous ambulatory peritoneal dialysis: interactions of resident cells during inflammation in the peritoneal cavity, Perit.Dial Int. 13 Suppl 2, Seite S282-S285. URL: PM:0008399589

[31] Topley, N. und Williams, J. D. (1994): Role of the peritoneal membrane in the control of inflammation in the peritoneal cavity, Kidney Int.Suppl 48, Seite S71-S78. URL: PM:0007700045

[32] Schindler, R.; Mancilla, J.; Endres, S.; Ghorbani, R.; Clark, S. C. und Dinarello, C. A. (1990): Correlations and interactions in the production of interleukin-6 (IL- 6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF, Blood 75 [1], Seite 40-47. URL: PM:2294996

[33] Kunkel, S. L.; Wiggins, R. C.; Chensue, S. W. und Larrick, J. (1986): Regulation of macrophage tumor necrosis factor production by prostaglandin E2, Biochem.Biophys.Res.Commun. 137 [1], Seite 404-410. URL: PM:3459461

[34] Kunkel, S. L. und Chensue, S. W. (1985): Arachidonic acid metabolites regulate interleukin-1 production, Biochem.Biophys.Res.Commun. 128 [2], Seite 892-897. URL: PM:3922370

[35] Plum, J.; Lordnejad, M. R. und Grabensee, B. (1998): Effect of alternative peritoneal dialysis solutions on cell viability, apoptosis/necrosis and cytokine expression in human monocytes [published erratum appears in Kidney Int 1998 Aug;54(2):677], Kidney Int. 54 [1], Seite 224-235. URL: PM:0009648083

[36] Jörres, A.; Ludat, K.; Sander, K.; Dunkel, K.; Lorenz, F.; Keck, H.; Frei, U. und Gahl, G. M. (1996): The peritoneal fibroblast and the control of peritoneal inflammation, Kidney Int.Suppl 56, Seite S22-S27. URL: PM:0008914050

[37] Jörres, A.; Gahl, G. M.; Topley, N.; Neubauer, A.; Ludat, K.; Muller, C. und Passlick-Deetjen, J. (1994): In-vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose-polymer-based solutions, Nephrol Dial Transplant 9 [7], Seite 785-790. URL: PM:0007970120

[38] Hurst, SM; Wilkinson, T. S.; McLoughlin, R. M.; Jones, S.; Horluchi, S.; Yamamoto, N.; Rose-John, S.; Fuller, G. M.; Topley, N und Jones, S. A. (2001): IL-6 and Its Soluble Receptor Orchestrate a Temporal Switch in the Pattern of Leukocyte Recruitment Seen during Acute Inflammation., Immunity 14, Seite 705-714.

[39] Samuelsson, B. (1983): Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation, Science 220 [4597], Seite 568-575. URL: PM:6301011

[40] Samuelsson, B. (1983): Leukotrienes: a new class of mediators of immediate hypersensitivity reactions and inflammation, Adv.Prostaglandin Thromboxane Leukot.Res. 11, Seite 1-13. URL: PM:6303067

[41] Jörres, A.; Bender, T. O.; Finn, A.; Witowski, J.; Frohlich, S.; Gahl, G. M.; Frei, U.; Keck, H. und Passlick-Deetjen, J. (1998): Biocompatibility and buffers: effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function, Kidney Int. 54 [6], Seite 2184-2193. URL: PM:0009853285

[42] Holmes, C. J. und Shockley, T. R. (2000): Strategies to Reduce Glucose Exposure in Peritoneal Dialysis, Perit.Dial Int. 20 [Suppl. 2], Seite 37-41.

[43] Faller, B. (1996): Amino acid-based peritoneal dialysis solutions, Kidney Int.Suppl 56, Seite S81-S85. URL: PM:0008914059

[44] Kjellstrand, P.; Martinson, E.; Wieslander, A. und Holmquist, B. (1995): Development of toxic degradation products during heat sterilization of glucose-containing fluids for peritoneal dialysis: influence of time and temperature, Perit.Dial Int. 15 [1], Seite 26-32. URL: PM:0007734557

[45] Kjellstrand, P.; Martinson, E.; Wieslander, A.; Kjellstrand, K.; Jeppsson, E.; Svensson, E.; Jarkelid, L.; Linden, T. und Olsson, L. F. (2001): Degradation in peritoneal dialysis fluids may be avoided by using low pH and high glucose concentration, Perit.Dial.Int. 21 [4], Seite 338-344. URL: PM:11587395

[46] Aufricht, C.; Endemann, M.; Bidmon, B.; Arbeiter, K.; Mueller, T.; Regele, H.; Herkner, K. und Eickelberg, O. (2001): Peritoneal dialysis fluids induce the stress response in human mesothelial cells, Perit.Dial.Int. 21 [1], Seite 85-88. URL: PM:11280504

[47] Duwe, A. K.; Vas, S. I. und Weatherhead, J. W. (1981): Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro, Infect.Immun. 33 [1], Seite 130-135. URL: PM:7021420

[48] Breborowicz, A.; Rodela, H und Oreopoulos, G. D. (1992): Toxicity of osmotic solutes on human mesothelial cells in vitro., Kidney Int. 41 [5], Seite 1280-1285.

[49] Wieslander, A. P.; Nordin, M. K.; Kjellstrand, P. T. und Boberg, U. C. (1991): Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929, Kidney Int. 40 [1], Seite 77-79. URL: PM:0001921158

[50] Gotloib, L.; Wajsbrot, V.; Shostak, A. und Kushnier, R. (1999): Effect of Hyperosmolality upon the Mesothelial Monolayer Exposed in vivo and in situ to a Mannitol-Enriched Dialysis Solution, Nephron 81, Seite 301-309.

[51] Passlick-Deetjen, J. und Jaeckle-Meyer, I. (1998): Bicarbonate buffers in peritoneal dialysis, Artif.Organs 22 [1], Seite 17-19. URL: PM:0009456221

[52] Mackenzie, R. K.; Jones, S.; Moseley, A.; Holmes, C. J.; Argyle, R.; Williams, J. D.; Coles, G. A.; Pu, K.; Faict, D. und Topley, N. (2000): In vivo exposure to bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function, Am J Kidney Dis. 35 [1], Seite 112-121. URL: PM:0010620552

[53] Witowski, J.; Breborowicz, A.; Topley, N.; Martis, L.; Knapowski, J. und Oreopoulos, D. G. (1997): Insulin stimulates the activity of Na+/K(+)-ATPase in human peritoneal mesothelial cells, Perit.Dial Int. 17 [2], Seite 186-193. URL: PM:0009159841

[54] Nilsson-Thorell, C. B.; Muscalu, N.; Andren, A. H.; Kjellstrand, P. T. und Wieslander, A. P. (1993): Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes, Perit.Dial Int. 13 [3], Seite 208-213. URL: PM:0008369351

[55] Wieslander, A. P.; Kjellstrand, P. T. und Rippe, B. (1995): Heat sterilization of glucose-containing fluids for peritoneal dialysis: biological consequences of chemical alterations, Perit.Dial Int. 15 [7 Suppl], Seite S52-S59. URL: PM:0008555328

[56] Jellum E; Borresen HC und Eldjarn L (1973): The presence of furan derivatives in patients receiving fructose-containing solutions intravenously, Clin.Chim.Acta 47 [2], Seite 191-201.

[57] Linden T; Forsback, G.; Deppisch, R.; Henle T und Wieslander, A. (2001): 3-Deoxyglucosone, a promotor of advanced glycation end products in fluids for peritoneal dialysis, Perit.Dial Int. 1998 [18], Seite 290-293.

[58] Linden T; Deppisch, R.; Kjellstrand, P.; Forsbäck, G. und Wieslander, A. (2002): 3,4-Dideoxyglucosone-3-Ene (3,4-DGE), a Cytotoxic Glucose Degradation Product in Peritoneal Dialysis Fluids, Perit.Dial Int. 22 [1], Seite 102-102.

[59] Linden, T.; Cohen, A.; Deppisch, R.; Kjellstrand, P. und Wieslander, A. (2002): 3,4-Dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis, Kidney Int. 62 [2], Seite 697-703.

[60] Martinson, E.; Wieslander, A.; Kjellstrand, P. und Boberg, U. (1992): Toxicity of heat sterilized peritoneal dialysis fluids is derived from degradation of glucose, ASAIO J. 38 [3], Seite M370-M372. URL: PM:1457884

[61] Witowski, J.; Korybalska, K.; Wisniewska, J.; Breborowicz, A.; Gahl, G. M.; Frei, U.; Passlick-Deetjen, J. und Jorres, A. (2000): Effect of glucose degradation products on human peritoneal mesothelial cell function, J Am Soc Nephrol 11 [4], Seite 729-739. URL: PM:0010752532

[62] Witowski, J.; Wisniewska, J.; Korybalska, K.; Bender, T. O.; Breborowicz, A.; Gahl, G. M.; Frei, U.; Passlick-Deetjen, J. und Jorres, A. (2001): Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells, J.Am.Soc.Nephrol. 12 [11], Seite 2434-2441. URL: PM:11675420

[63] Dawnay, A. B. St. J. und Millar, D. J. (1997): Glycation and Advanced Glycation End-Product Formation with Icodextrin and Dextrose, Perit.Dial Int. 17, Seite 52-58.

[64] Nakayama, M.; Kawaguchi, Y.; Yamada, K.; Hasegawa, T.; Takazoe, K.; Katoh, N.; Hayakawa, H.; Osaka, N.; Yamamoto, H.; Ogawa, A.; Kubo, H.; Shigematsu, T.; Sakai, O. und Horiuchi, S. (1997): Immunohistochemical detection of advanced glycosylation endproducts in the peritoneum and its possible pathophysiological role in CAPD, Kidney Int. 51, Seite 182-186.

[65] Inagi, R.; Miyata, T.; Yamamoto, T.; Suzuki, D.; Urakami, K.; Saito, A.; Van Ypersele, De Strihou und Kurokawa, K. (1999): Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis, FEBS Lett. 463 [3], Seite 260-264. URL: PM:10606733

[66] Miyata, T.; Sugiyama, S.; Saito, A. und Kurokawa, K. (2001): Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"), Kidney Int.Suppl 78, Seite S25-S31. URL: PM:11168978

[67] Mandl-Weber, S.; Cohen, C. D.; Haslinger, B.; Kretzler, M. und Sitter, T. (2002): Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells, Kidney Int. 61 [2], Seite 570-578.

[68] De Vriese, A. S.; Mortier, S. und Lameire, N. H. (2001): Glucotoxicity of the peritoneal membrane: the case for VEGF, Nephrol.Dial.Transplant. 16 [12], Seite 2299-2302. URL: PM:11733619

[69] Topley, N. (1997): In vitro biocompatibility of bicarbonate-based peritoneal dialysis solutions, Perit.Dial Int. 17 [1], Seite 42-47. URL: PM:0009068021

[70] Brunkhorst, R. und Mahiout, A. (1995): Pyruvate neutralizes peritoneal dialysate cytotoxicity: maintained integrity and proliferation of cultured human mesothelial cells, Kidney Int. 48 [1], Seite 177-181. URL: PM:0007564075

[71] Shostak, A.; Gotloib, L.; Kushnier, R. und Wajsbrot, V. (2000): Protective effect of pyruvate upon cultured mesothelial cells exposed to 2 mM hydrogen peroxide, Nephron 84 [4], Seite 362-366. URL: PM:0010754414

[72] Hanning, R. M.; Balfe, J. W. und Zlotkin, S. H. (1987): Effectiveness and nutritional consequences of amino acid-based vs glucose-based dialysis solutions in infants and children receiving CAPD, Am J Clin.Nutr. 46 [1], Seite 22-30. URL: PM:0003300250

[73] Young, G. A.; Dibble, J. B.; Taylor, A. E.; Kendall, S. und Brownjohn, A. M. (1989): A longitudinal study of the effects of amino acid-based CAPD fluid on amino acid retention and protein losses, Nephrol Dial Transplant 4 [10], Seite 900-905. URL: PM:0002515496

[74] Jones, M. R.; Gehr, T. W.; Burkart, J. M.; Hamburger, R. J.; Kraus, A. P., Jr.; Piraino, B. M.; Hagen, T.; Ogrinc, F. G. und Wolfson, M. (1998): Replacement of amino acid and protein losses with 1.1% amino acid peritoneal dialysis solution, Perit.Dial Int. 18 [2], Seite 210-216. URL: PM:0009576371

[75] Brulez, H. F.; van Guldener, C.; Donker, A. J. und ter Wee, P. M. (1999): The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass, Nephrol Dial Transplant 14 [1], Seite 154-159. URL: PM:0010052496

[76] Jones, M.; Kalil, R.; Blake, P.; Martis, L. und Oreopoulos, D. G. (1997): Modification of an amino acid solution for peritoneal dialysis to reduce risk of acidemia, Perit.Dial Int. 17 [1], Seite 66-71. URL: PM:0009068025

[77] Ronco, C. (1999): Peritoneal dialysis: the state of the art in Europe, Am J Kidney Dis. 33 [3], Seite I-Iii. URL: PM:0010070904

[78] Mistry, C. D.; Gokal, R. und Peers, E. (1994): A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis, Kidney Int. 46 [2], Seite 496-503. URL: PM:0007967363

[79] Posthuma, N.; ter Wee, P. M.; Verbrugh, H. A.; Oe, P. L.; Peers, E.; Sayers, J. und Donker, A. J. (1997): Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance, Nephrol Dial Transplant 12 [3], Seite 550-553. URL: PM:0009075139

[80] Woodrow, G.; Stables, G.; Oldroyd, B.; Gibson, J.; Turney, J. H. und Brownjohn, A. M. (1999): Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis, Nephrol Dial Transplant 14 [6], Seite 1530-1535. URL: PM:0010383020

[81] Peers, E. und Gokal, R. (1997): Icodextrin: overview of clinical experience, Perit.Dial Int. 17 [1], Seite 22-26. URL: PM:0009068018

[82] Wang, T.; Cheng, H. H.; Heimburger, O.; Waniewski, J.; Bergstrom, J. und Lindholm, B. (2000): Effect of peritonitis on peritoneal transport characteristics: glucose solution versus polyglucose solution, Kidney Int. 57 [4], Seite 1704-1712. URL: PM:0010760106

[83] Goldsmith, D.; Jayawardene, S.; Sabharwal, N. und Cooney, K. (2000): Allergic reactions to the polymeric glucose-based peritoneal dialysis fluid icodextrin in patients with renal failure., Lancet 355 [11], Seite 897.

[84] Jörres, A.; Topley, N.; Steenweg, L.; Muller, C.; Kottgen, E. und Gahl, G. M. (1992): Inhibition of cytokine synthesis by peritoneal dialysate persists throughout the CAPD cycle, Am J Nephrol 12 [1-2], Seite 80-85. URL: PM:0001415370

[85] Carmichael, J.; Degraff, W. G.; Gazdar, A. F.; Minna, J. D. und Mitchell, J. B. (1987): Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing, Cancer Res. 47 [4], Seite 936-942. URL: PM:0003802100

[86] Wieslander, A. P. (1996): Cytotoxicity of peritoneal dialysis fluid - is it related to glucose breakdown products?, Nephrol Dial Transplant 11 [6], Seite 958-959. URL: PM:0008671949

[87] Lamb, E. J.; Cattell, W. R. und Dawnay, A. B. St. J. (1995): In vitro formation of advanced glycation end products in peritoneal dialysis fluid, Kidney Int. 47, Seite 1768-1774.

[88] Zeier, M.; Schwenger, V.; Deppisch, R.; Haug, U.; Weigl, K.; Bahner, U.; Wanner, C.; Schneider, H.; Henle, T. und Ritz, E. (2003): Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavitiy and enter the systemic circulation?, Kidney Int. 63, Seite 298-305.

[89] Morgan, L. W.; Wieslander, A.; Davies, M.; Horiuchi, T.; Ohta, Y.; Beavis, M. J.; Craig, K. J.; Williams, J. D. und Topley, N (2003): Glucose degradation procuts (GDP) retard remesothelialization independently of D-glucose concentration., Kidney Int. 64 [5], Seite 1854-1866.

[90] Wieslander, A. P.; Deppisch, R.; Svensson, E.; Forsback, G.; Speidel, R. und Rippe, B. (1995): In vitro biocompatibility of a heat-sterilized, low-toxic, and less acidic fluid for peritoneal dialysis, Perit.Dial Int. 15 [2], Seite 158-164. URL: PM:0007612737

[91] Passlick-Deetjen, J. und Lage, C. (2000): Lactate-buffered and bicarbonate-buffered solutions with less glucose degradation products in a two-chamber system, Perit.Dial Int. 20 Suppl 2, Seite S42-S47. URL: PM:0010911642

[92] Cooker, L. A.; Luneburg, P.; Faict, D.; Choo, C. und Holmes, C. J. (1997): Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags, Perit.Dial Int. 17 [4], Seite 373-378. URL: PM:0009284465

[93] Zareie, M.; Hekking, L. H. P.; Welten, A. G. A.; Driesprong, B. A. J.; Schade-Eestermans, I. L.; Faict, D.; Leyssens, A.; Schalkwijk, C. G.; Beelen, R. H. J.; ter Wee, P. M. und van den Born, J (2003): Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo., Nephrol Dial Transplant 18, Seite 2629-2637.

[94] Rippe, B.; Simonsen, O; Heimbürger, O.; Christensson, A; Haraldsson, B; Stelin, G; Weiss, L; Nielsen, FD; Bro, S; Friedberg, M und Wieslander, A. (2001): Long-term effect of a peritoneal dialysis fluid with less glucose degradation products, Kidney Int. 59, Seite 348-357.

[95] Jonasson, P.; Albrektsson, A.; Ljungman, S.; Wieslander, A. und Braide, M. (2003): Peritoneal leukocyte survival and respiratory burst responses in patients treated with a low glucos degradation and high pH peritoneal dialysis fluid., Int.J Artif.Organs 26 [2], Seite 121-128.

[96] Brulez, H. F.; Heezius, E. C.; de Fijter, C. W.; Oe, L. P.; Verhoef, J. und Verbrugh, H. A. (1994): In vitro compatibility of a 1.1% amino acid containing peritoneal dialysis fluid with phagocyte function, Adv.Perit.Dial 10, Seite 241-244. URL: PM:0007999837

[97] Brulez, H. F.; Dekker, H. A.; Oe, P. L.; Verbeelen, D.; ter Wee, P. M. und Verbrugh, H. A. (1996): Biocompatibility of a 1.1% amino acid-containing peritoneal dialysis fluid compared to a 2.27% glucose-based peritoneal dialysis fluid, Nephron 74 [1], Seite 26-32. URL: PM:0008883016

[98] Garosi, G.; Gaggiotti, E.; Monaci, G.; Brardi, S. und Di Paolo, N. (1998): Biocompatibility of a peritoneal dialysis solution with amino acids: histological evaluation in the rabbit, Perit.Dial Int. 18 [6], Seite 610-619. URL: PM:0009932660

[99] Chan, T. M.; Leung, J. K. H.; Sun, Y.; Lai, K. N.; Tsang, R. C. W. und Yung, S. (2003): Different effects of amino acid-based and glucose-based dialysate from peritoneal dialysis patients on mesothelial cell ultrastructure and function., Nephrol Dial Transplant 18, Seite 1086-1094.

[100] Frampton, J. E. und Plosker, G. L. (2003): Icodextrin. A Review of its Use in Peritoneal Dialysis., Drugs 63 [19], Seite 2079-2105.

[101] Liberek, T.; Topley, N.; Mistry, C. D.; Coles, G. A.; Morgan, T.; Quirk, R. A. und Williams, J. D. (1993): Cell function and viability in glucose polymer peritoneal dialysis fluids, Perit.Dial Int. 13 [2], Seite 104-111. URL: PM:0008388260

[102] de Fijter, C. W.; Verbrugh, H. A.; Oe, L. P.; Heezius, E.; Donker, A. J.; Verhoef, J. und Gokal, R. (1993): Biocompatibility of a glucose-polymer-containing peritoneal dialysis fluid, Am J Kidney Dis. 21 [4], Seite 411-418. URL: PM:0008465822

[103] Rooney, O. B.; Dodd, P. D.; Gokal, R. und Walker, M. G. (1996): Dialysis fluid cytotoxicity and inhibition of host defence in cultured human mesothelial cells are neutralized rapidly with incubation in the peritoneum, Nephrol Dial Transplant 11 [12], Seite 2472-2477. URL: PM:0009017625

[104] Cooker, L. A.; Choo, C. G.; Luneburg, P.; Lamela, J. und Holmes, C. J. (1999): Effect of icodextrin peritoneal dialysis solution on cell proliferation in vitro, Adv.Perit.Dial 15, Seite 17-20. URL: PM:0010682065

[105] Gotloib, L.; Shostak, A. und Wajsbrot, V. (2000): Effects of osmotic agents upon the in vivo exposed mesothelial monolayer, Perit.Dial Int. 20 Suppl 2, Seite S11-S14. URL: PM:0010911636

[106] Gotloib, L.; Wajsbrot, V. und Shostak, A. (2002): Mesothelial Dysplastic Changes and Lipid Peroxidation Induced by 7.5% Icodextrin., Nephron 92, Seite 142-155.

[107] Gotloib, L.; Wajsbrot, V. und Shostak, A. (2003): Icodextrin-Induced Lipid Peroxidation Disrupts The Mesothelial Cell Cycle Engine, Free Radical Biology & Medicine 34 [4], Seite 419-428.

[108] Beavis, M. J.; Williams, J. D.; Hoppe, J. und Topley, N. (1997): Human peritoneal fibroblast proliferation in 3-dimensional culture: modulation by cytokines, growth factors and peritoneal dialysis effluent, Kidney Int. 51 [1], Seite 205-215. URL: PM:0008995735

[109] Jörres, A.; Gahl, G. M. und Frei, U. (1994): Peritoneal dialysis fluid biocompatibility: does it really matter?, Kidney Int.Suppl 48, Seite S79-S86. URL: PM:0007700046

[110] Witowski, J.; Topley, N.; Jorres, A.; Liberek, T.; Coles, G. A. und Williams, J. D. (1995): Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis, Kidney Int. 47 [1], Seite 282-293. URL: PM:0007731159


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
11.12.2006